Hypersomnia Foundation’s Post

The Vibrance-1 Study for Narcolepsy Type 1 is Now Enrolling. NOW RECRUITING people diagnosed with narcolepsy type 1 (NT1) aged 18 to 70. The purpose of this study is to research the safety and effectiveness of an investigational study drug taken orally once daily and how it may work in adults with NT1. Individuals with NT1 may be eligible for the Vibrance-1 Study. Orexin is a chemical in the brain that helps regulate the sleep/wake cycle. The investigational study drug, ALKS 2680, is an orexin-2 receptor agonist and may improve symptoms of sleep disorder, such as excessive daytime sleepiness (EDS) and cataplexy, in patients with NT1. Individuals will be evaluated by the study team to determine their eligibility to participate in this research. Each individual who qualifies will receive either the study drug or a placebo, as well as study-related medical exams and study-related laboratory tests, at no cost. Compensation for time and travel may also be available. To learn more: Visit VibranceStudies.com

NOW RECRUITING people diagnosed with narcolepsy type 1 (NT1) aged 18 to 70. The purpose of this study is to research the safety and effectiveness of an investigational study drug taken orally once daily and how it may work in adults with NT1. Individuals with NT1 may be eligible for the Vibrance-1 Study. Orexin is a chemical in the brain that helps regulate the sleep/wake cycle. The investigational study drug, ALKS 2680, is an orexin-2 receptor agonist and may improve symptoms of sleep disorder, such as excessive daytime sleepiness (EDS) and cataplexy, in patients with NT1. Individuals will be evaluated by the study team to determine their eligibility to participate in this research. Each individual who qualifies will receive either the study drug or a placebo, as well as study-related medical exams and study-related laboratory tests, at no cost. Compensation for time and travel may also be available. To learn more click here: https://lnkd.in/e9rfPfwy CTR-003484

In clinical practice, atrial fibrillation is considered to be the most common arrhythmia and this is because the population is getting older and also because the population has risk factors that are not well controlled. It is precisely the elderly who are most vulnerable to this change in heart rhythm. It is specifically individuals with poorly controlled hypertension who are at the highest risk. The main complications related to AF are stroke, heart failure, increased risk of death and hospitalization rates. The main ways to prevent these complications is to reduce the risk of AF developing through periodic clinical assessments, control of hypertension, diabetes, sleep apnea, weight loss, regular physical activity and other special precautions. Anticoagulation is imperative in those with a CHA2DS2VASc score (Cardiac failure; Hypertention; Age >75 y; Stroke history; Vascular disease; Age > 64y; Female sex) above 2 for men and above 3 for women; treating symptoms with either rhythm or heart rate control and, finally, treating or abolishing risk factors. This approach helps to reduce recurrences and improve prognosis. When this arrhythmia is suspected and has not yet been diagnosed, 7-day Holter monitoring is one of the most useful tools. This technique increases the likelihood of confirmation by 30% or more (depending on the population and the patient's clinical characteristics). This approach helps to implement early treatment and reduce complications.

SeattleNTC is participating in the prospective, multi-site Open-label Optimization (OLO) clinical research program to assess the effectiveness of the SAINT™ neuromodulation system to treat Major Depressive Disorder. Recruitment is active! Patients coming from a distance should expect to spend 2 weeks in the Seattle/Bellevue area -- the first week to get the fMRI, the second week to receive the treatment. OLO Study Summary: -         Primary objective - to assess the effectiveness of the SAINT neuromodulation system in the treatment of MDD as measured by the Clinical Global Impression Improvement Scale (GCI-I) at the end of the treatment (cessation of stimulation). -         Population - up to 1,000 adult subjects in a major depressive episode, who have failed to receive satisfactory improvement from a prior antidepressant medication in the current episode, are eligible to participate in the study if they are deemed to be appropriate candidates for transcranial magnetic stimulation (TMS). -         Study duration - expected to be approximately four years, and the study duration per subject is anticipated to be approximately one year. 

Cerebral palsy denotes a cluster of enduring motor afflictions manifesting in infancy, stemming from aberrant brain development or injury impacting motor control centers. This condition precipitates disturbances in muscle coordination, reflex integration, and postural stability. Clinical manifestations encompass a spectrum of motor impairments, with accompanying cognitive deficits, seizures, or sensory impairments occasionally present. Therapeutic modalities, pharmaceutical interventions, and surgical interventions are often employed to ameliorate functionality and enhance the individual's quality of life. Timely intervention assumes paramount significance in optimizing prognosis and mitigating long-term sequelae.Physiotherapy interventions include exercises and counselling of child and parents to promote quality of life and slow down the progression of disease.

Tendinopathy describes a spectrum of changes that occur in damaged tendons, leading to pain and reduced function that remains extremely challenging for all clinicians. There is an increasing awareness of the influence that psychological and psychosocial components, such as self-efficacy and fear-avoidance, have on rehabilitation outcomes in musculoskeletal medicine. Although it is widely accepted that psychological/psychosocial factors exist in tendinopathy, there is currently a distinct lack of trials measuring how these factors affect clinical outcomes. Biopsychosocial treatments acknowledge and address the biological, psychological and social contributions to pain and disability are currently seen as the most efficacious approach to chronic pain. Addressing and modulating these factors are crucial in the pathway of personalised treatments in tendinopathy and offer a real opportunity to drive positive outcomes in patients. In this education review, we also provide the current evidence-based guidance on psychological and psychosocial developments in musculoskeletal medicine and how these may be translated to treating tendinopathy using a biopsychosocial model.

Deprescribing Benzodiazepines : Benzodiazepine receptor agonists, too, often can be deprescribed. These drugs should not be prescribed to promote sleep on a long-term basis. Yet clinicians commonly encounter patients who have been taking them for more than a year, said pharmacist Betsy Thomas, assistant adjunct professor of family medicine at the University of Alberta. The medications “are usually fairly effective for the first couple of weeks to about a month, and then the benefits start to decrease, and we start to see more harms,” she said. Some of the harms that have been associated with continued use of benzodiazepine receptor agonists include delayed reaction time and impaired cognition, which can affect the ability to drive, the risk for falls, and the risk for hip fractures, she noted. Some research suggests that these drugs are not an option for treating insomnia in patients aged 65 years or older. Clinicians should encourage tapering the use of benzodiazepine receptor agonists to minimize dependence and transition patients to nonpharmacologic approaches such as cognitive behavioral therapy to manage insomnia, she said. #Medscape news

How Do Antipsychotic Medicine Affect Our Body? 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐏𝐃𝐅 https://lnkd.in/gehkpcce The antipsychotic medicine market is experiencing steady growth, driven by advancements in neuroscience, increased awareness of mental health disorders, and evolving treatment paradigms. With the global rise in cases of schizophrenia, bipolar disorder, and other psychotic conditions, the demand for innovative and effective antipsychotic drugs is higher than ever. Key trends shaping this market include: Shift Toward Atypical Antipsychotics: Atypical antipsychotics, with their lower risk of severe side effects compared to typical antipsychotics, are gaining traction. These medications also demonstrate efficacy in treating conditions beyond schizophrenia, such as depression and anxiety. Long-Acting Injectables (LAIs): LAIs are becoming the preferred option for many patients and caregivers due to improved medication adherence and reduced relapse rates. This trend is encouraging pharmaceutical companies to invest in developing new formulations. Precision Medicine and Digital Therapies: Advances in pharmacogenomics and AI-driven tools are enabling personalized treatment approaches, ensuring patients receive medications tailored to their genetic profile and clinical needs. Global Market Expansion: Emerging economies in Asia-Pacific and Latin America are witnessing rapid market growth due to increasing healthcare access, government initiatives, and destigmatization of mental health issues. However, challenges such as the high cost of novel drugs, stigma surrounding mental health, and unmet needs in drug efficacy and safety continue to be areas requiring attention. What innovations or trends in the antipsychotic medicine market excite you the most? Let's discuss! #Antipsychotics #MentalHealth #Pharmaceuticals #Biotechnology #Innovation

Vigorous Physical Activity Linked to Reduced Cognitive Decline in Patients with High-Risk Hypertension: Study reveals vigorous physical activity correlates with lower rates of cognitive impairment in hypertensive patients. #finance #pharmacy #lifesciences